News

CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting

CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

CE-marked clinical decision support platform enables laboratories to provide best-in-class diagnostics of genetic diseases

Newly established WGS recommendations published in the European Journal of Human Genetics

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential […]

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, November 24, 2021 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused […]

CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 30, 2022 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021 and provided a business update.

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced today that CEO Kim Stratton will speak at the sixteenth annual BIO-Europe Spring conference on March 31, 2022, at 3:00 p.m. CEST/9:00 a.m. EDT.

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial results for the quarter and full year ended December 31, 2021, on Wednesday, March 30, 2022, and will host a conference call and webcast to discuss these results at 2 p.m. CEST / 8 a.m. EDT that day.

A new collaborative research project has now been initiated, which may be used to validate rare genetic causes of neurogenerative diseases as potential targets for specific diseases. Data will be generated based on an existing cohort of patient samples from CENTOGENE’s Bio/Databank.

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 22, 2022 (GLOBE NEWSWIRE – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company […]

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 08, 2022 (GLOBE NEWSWIRE – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company […]

Dr. Andrin Oswald resigns as CEO due to prolonged medical leave; Kim Stratton elected as successor CAMBRIDGE, Mass. and ROSTOCK, […]

Enables refocusing on core business of delivering valuable, data-driven insights to patients, and pharmaceutical companies globally EUR 15 million private […]